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Lipid rafts and mitochondria are promising targets in cancer therapy. The synthetic antitumor alkyl-lysophospholipid analog
edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) has been reportedto target lipid rafts. Here,wehavefound
that edelfosine induced loss of mitochondrial membrane potential and apoptosis in human cervical carcinoma HeLa cells, both
responses being abrogated by Bcl-xL overexpression. We synthesized a number of new ﬂuorescent edelfosine analogs, which
preserved the proapoptotic activity of the parent drug, and colocalized with mitochondria in HeLa cells. Edelfosine induced
swelling in isolated mitochondria, indicating an increase in mitochondrial membrane permeability. This mitochondrial swelling
was independent of reactive oxygen species generation. A structurally related inactive analog was unable to promote
mitochondrial swelling, highlighting the importance of edelfosine molecular structure in its effect on mitochondria. Raft
disruption inhibited mitochondrial localization of the drug in cells and edelfosine-induced swelling in isolated mitochondria.
Edelfosine promoted a redistribution of lipid rafts from the plasma membrane to mitochondria, suggesting a raft-mediated link
between plasma membrane and mitochondria. Our data suggest that direct interaction of edelfosine with mitochondria
eventually leads to mitochondrial dysfunction and apoptosis. These observations unveil a new framework in cancer
chemotherapy that involves a link between lipid rafts and mitochondria in the mechanism of action of an antitumor drug, thus
opening new avenues for cancer treatment.
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Mitochondria are central hubs for intrinsic apoptotic pathways
that are activated by cellular stress and injury, playing a
critical role in physiological and drug-induced apoptosis.
Mitochondria contain a number of proapoptotic proteins,
which are released following the formation in the mitochon-
drial membrane of the so-called permeability transition pore
(PTP),
1 thus leading to the generation of the apoptosome and
the triggering of the mitochondrial intrinsic pathway of cell
death. Recently, mitochondria in cancer cells have emerged
as the Achilles’ heel for tumor destruction. Anticancer agents
speciﬁcally targeting cancer cell mitochondria, referred to as
‘mitocans’, act by destabilizing these organelles, unleashing
their apoptogenic potential and resulting in the efﬁcient death
of malignant cells.
2
Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phos-
phocholine) is the prototype compound of a family of
promising synthetic antitumor drugs collectively known as
alkyl-lysophospholipid analogs or antitumor ether lipids.
3–5
This group of compounds also includes miltefosine, marketed
under the trade name of Miltex (Baxter Oncology GmbH,
Halle/Westfalen, Germany) as a topical drug for the palliative
treatment of cutaneous metastases from breast cancer, and
perifosine, currently in phase II clinical trials.
6 Edelfosine
showsafﬁnityforcholesterol,
7,8andhasbeenreported tokilla
wide variety of tumor cells through its accumulation in lipid
rafts,
9–12 which are membrane microdomains enriched in
cholesterol and sphingolipids. Edelfosine treatment led to
alterations in the biophysical features as well as in the protein
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7,10,13,14 Edelfosine has also been
found to accumulate inthe endoplasmic reticulum of solid tumor
cells,
15 promoting an endoplasmic reticulum stress response.
16
Yet, irrespective of the edelfosine action on lipid rafts or
endoplasmic reticulum, the apoptotic response triggered by this
drug requires the participation of mitochondrial-mediated
signaling, this latter acting as the critical event that leads
eventually to the demise of the tumor cell.
16,17 Edelfosine-
induced apoptosis involves disruption of the mitochondrial
transmembrane potential (DCm) and release of mitochondrial
cytochromectothecytosolinanumberofhematologicalcancer
cells.
17,18 Because both lipid rafts and mitochondria have been
involved in the apoptotic response induced by edelfosine, we
analyzed whether edelfosine interacted directly with
mitochondria and whether lipid rafts were implicated in a
mitochondrial-dependent action of the antitumor drug.
Results
Edelfosine induces apoptosis in HeLa cells through
a mitochondrial-mediated process. We found that
edelfosine induced disruption of DCm and apoptosis in
human cervix epithelioid carcinoma HeLa cells in a time-
dependent manner, assessed through 3,30-dihexyloxa-
carbocyanine iodide (DiOC6(3)) ﬂuorescence and cell cycle
analysis (hypodiploidy) by ﬂow cytometry (Figure 1a).
Edelfosine induced DCm loss before the onset of apoptosis
(Figure 1a). Ectopic overexpression of Bcl-xL by gene
transfer in HeLa cells
16 prevented both DCm disruption and
DNA fragmentation (Figure 1b). These results indicate the
involvement of mitochondria in edelfosine-induced apoptosis
in HeLa cells.
Synthesis of new ﬂuorescent analogs of edelfosine
preserving the parent drug’s proapoptotic activity. To
visualize the subcellular localization of edelfosine in HeLa
cells, we used ﬂuorescent analogs of the alkyl ether phos-
pholipid. Fluorescent analogs were designed in such a way
that the amphipathic properties and the main structural
motifs of the alkyl ether lipid
3 were preserved (Supplemen-
tary Information). High ﬂuorescence yield and good photo-
stability were also sought for, whenever possible. Thus, we
produced ﬁrst a family of emitting analogs in which a
fragment of the original linear polymethylene chain was
replaced by a conjugated all-(E)-phenyltetraene, or a conju-
gated all-(E)-phenyltrienyne chromophore, to yield PTE-ET
(all-(E)-1-O-(150-phenylpentadeca-80,100,120,140-tetraenyl)-
2-O-methyl-rac-glycero-3-phosphocholine) and PTRI-ET
(all-(E)-1-O-(150-phenylpentadeca-100,120,140-trien-80-ynyl)-2-
O-methyl-rac-glycero-3-phosphocholine) analogs, respecti-
vely (Figure 2). The proapoptotic activity of these
blue-emitting alkyl lipids was similar to that of the parent
compound (Figure 3), as assessed by their ability to induce
apoptosis in HeLa cells, although their photostability under
the intense near-UV laser excitation of the microscope was
poor (Supplementary Information). Both ﬂuorescence yield
and resistance to photodegradation were largely improved in
the second class of analogs synthesized here, which showed
convenient excitation and emission spectra in the visible
range. This was made possible by attaching a 2-substituted
borondiﬂuorodipyrromethene (BODIPY, BDP) ﬂuorophore to
the alkyl chain of edelfosine (Supplementary Information), to
generate Et-BDP-ET (1-O-(110-(600-ethyl-100,300,500,700-tetra-
methyl-400,400-diﬂuoro-400-bora-3a00,4a00-diaza-s-indacen-200-yl)
undecyl)-2-O-methyl-rac-glycero-3-phosphocholine) and
Yn-BDP-ET (1-O-(130-(100,300,500,700-tetramethyl-400,400-diﬂuoro-
400-bora-3a00,4a00-diaza-s-indacen-200-yl)tridec-120-ynyl)-2-O-
methyl-rac-glycero-3-phosphocholine) analogs (Figure 2). In
spite of this substantial change in the lipid structure, these
BODIPY analogs also showed a high proapoptotic acti-
vity, similar to that of the parent drug edelfosine (Figure 3).
The synthesis and characterization of the new edelfosine
analogs, which are structurally related to physiological
lysophosphatidylcholine molecule (Figure 2), are described
in the Supplementary Information.
Fluorescent edelfosine analogs colocalize with
mitochondria in HeLa cells. The edelfosine ﬂuorescent
Figure 1 Involvement of mitochondria in edelfosine-induced apoptosis in HeLa
cells. (a) Time course of the effects of edelfosine on DCm disruption and induction
ofapoptosisinHeLacells.Cellsweretreatedwith10mMedelfosinefortheindicated
times,andpercentagesofcellswithdisruptedDCm(DioC6(3)
low)andshowingDNA
degradation (hypodiploidy in cell cycle analysis) were measured by ﬂow cytometry,
as described in the Materials and Methods section. (b) Prevention of edelfosine-
induced DCm disruption and apoptosis by overexpression of Bcl-xL. HeLa cells
transfected with empty vector (HeLa-neo) and Bcl-xL (HeLa-Bcl-xL) were treated
with 10mM edelfosine for the indicated times, and percentages of cells with
disrupted DCm (DioC6(3)
low) and showing DNA degradation (hypodiploidy in cell
cycle analysis) were measured as above. Data are means±S.D. of three
independent experiments
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2
Cell Death and Diseaseanalog PTE-ET (Figure 2) has been shown to behave as
a bona ﬁde analog to analyze edelfosine localization in the
cell.
10,15 We found that PTE-ET colocalized with mito-
chondria in HeLa cells (Figure 4), which showed a large
cytoplasm/nucleus ratio, thus allowing a good deﬁnition of
intracellular structures. Mitochondria were identiﬁed by
using the cell-permeant mitochondrion selective probe
MitoTracker (Molecular Probes, Eugene, OR, USA). As
shown in Figure 4, colocalization of edelfosine and
mitochondria was detected by the onset of apoptosis (see
Figures 1 and 4). PTE-edelfosine ﬂuorescence was weak
and rapidly bleached, thus preventing the use of confocal
microscopy analysis,
10,15 but the modest blue ﬂuorescence
of this compound allowed us to identify the subcellular
localization of edelfosine. The ﬂuorescent PTRI-ET analog
also colocalized with mitochondria (Figure 5). Both PTE-ET
and PTRI-ET share analogous ﬂuorescence traits with
a rather poor ﬂuorescence yield and photostability under
the intense near-UV laser excitation of the microscope
(Supplementary Information). To improve resolution to gain
a further insight into the subcellular localization of edelfosine,
we used the novel Et-BDP-ET and Yn-BDP-ET analogs
(Figure 2), which allowed us to visualize the subcellular
localization of the ﬂuorescent compounds in HeLa cells
through confocal microscopy, as the ﬂuorescent signal was
more stable. This second class of edelfosine analogs, Et-
BDP-ET and Yn-BDP-ET (Figure 2), containing a BODIPY
ﬂuorophore attached to the alkyl chain of edelfosine, had a
higher ﬂuorescence yield and resistance to photodegradation
than the above PTE-ET and PTRI-ET (Supplementary Infor-
mation). By using the ﬂuorescent edelfosine analogs
Et-BDP-ET and Yn-BDP-ET, we found a remarkable colocali-
zation between these compounds and mitochondria, which
were detected as a branched ﬁlament network (Figure 5).
Incorporation of the above ﬂuorescent analogs in HeLa cells
was blocked by adding the parent drug edelfosine (data not
shown), further supporting the use of the above compounds
as reliable ﬂuorescent analogs of edelfosine for in situ
subcellular localization studies of the drug.
Furthermore, the location of edelfosine in mitochondria was
mediated bylipid rafts,becausewhenHeLacellsweretreated
with 2.5mg/ml methyl-b-cyclodextrin (MCD) to deplete cho-
lesterol and disrupt lipid rafts,
14,17,19 edelfosine localization in
mitochondria was prevented (data not shown).
Edelfosine affects isolated mitochondria. As the above
results suggested that edelfosine interacted with mito-
chondria in HeLa cells, we analyzed whether this drug was
able to affect isolated mitochondria. We examined whether
edelfosine might act as an inducer of the PTP opening in
isolated liver mitochondria. As opening of the PTP is followed
by an increase of inner membrane permeability to solutes
with a molecular mass of o1500Da, the resulting increase in
mitochondrial volume (swelling) can be monitored by a
O
7 4 Ph O
OMe
PTE-ET
3
Ph
O
7 O
OMe
PTRI-ET
E
E
N
B
F2
N O
11
O
OMe
N
B
F2
N
9 O
OMe
O
Et-BDP-ET
Yn-BDP-ET
P
O
NMe3
O
O
O
15
O
OR1
PC
PC
PC
PC
PC
PC =
O O
OH
R2 PC
O
LysoPC
(R2 = acyl group chain)
edelfosine (EDLF or ET): R1 = Me
ET-18-OH: R1 = H
-
+
Figure 2 Chemical structures of edelfosine (EDLF, ET), the structurally related
inactive analog ET-18-OH, the related physiological compound lysophosphatidyl-
choline (LysoPC) and the ﬂuorescent analogs of edelfosine PTE-ET, PTRI-ET,
Et-BDP-ET and Yn-BDP-ET. The chemical structure of phosphatidylcholine (PC)
is also shown
Figure 3 Fluorescent analogs preserve the proapoptotic activity of edelfosine.
HeLa cells were treated with the parent drug edelfosine (EDLF) or with the distinct
ﬂuorescentanalogsPTE-ET,PTRI-ET,Et-BDP-ETandYn-BDP-ETattheindicated
concentrations for 24h, and apoptosis was then quantitated as percentage of cells
in the sub-G1 region (hypodiploidy) in cell cycle analysis by ﬂow cytometry.
Untreated control cells were run in parallel. Data are means±S.D. of four
independent experiments
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3
Cell Death and Diseasedecrease in the absorbance at 540nm.
20 Exposure of
mitochondria to edelfosine (5–50mM) induced a rapid loss
of absorbance, indicating mitochondrial swelling (Figures 6a
and b). Total decrease in absorbance following exposure to
edelfosine 50mM was 26.7±0.1% (n¼6). This effect of
edelfosine on mitochondrial swelling was dependent on its
ether lipid molecular structure, as an structurally related
inactive analog, ET-18-OH (1-O-octadecyl-rac-glycero-3-
phosphocholine; Figure 2), in which the methoxy group in
the sn-2 position was replaced by an OH group, was unable
to induce swelling (Figures 6a and b) and apoptosis.
3 We
next examined the effect of cyclosporin A (CsA), which has
been reported to prevent DCm disruption, and it is considered
as a prototypical inhibitor of the mitochondrial PTP.
21 We
found that CsA partially inhibited mitochondrial swelling
induced by edelfosine (10mM) in isolated mitochondria
(Figure 6c). We also found that CsA (10mM) failed to inhibit
this response to higher doses of edelfosine and in long-term
experiments (data not shown). This ﬁnding is in agreement
with previous studies reporting that the pharmacological
effects of CsA on mitochondrial PTP, which prevent
apoptosis-associated DCm loss, are transitory.
22 Taken
together, these data indicate that edelfosine induces mito-
chondrial swelling in a concentration-dependent manner, and
therefore edelfosine is able to affect directly mitochondria in a
way that might promote cancer cell death.
Figure 4 PTE-ET colocalizes with mitochondria in HeLa cells. Cells were incubated with 10mM phenyltetraene analog of edelfosine (PTE-ET, blue ﬂuorescence) for the
indicated times, and the location of mitochondria was examined using MitoTracker (MIT, red ﬂuorescence). Areas of colocalization between PTE-ET and mitochondria in the
PTE-ETþMIT panels are purple. The corresponding differential interference contrast (DIC) images are also shown. Images are representative of three independent
experiments. Bar, 20mm
Figure 5 Newly synthesized edelfosine ﬂuorescent analogs colocalize with mitochondria. HeLa cells were incubated for 12h with 10mM of the edelfosine (EDLF)
ﬂuorescent analogs PTRI-ET (blue ﬂuorescence), Et-BDP-ET (green ﬂuorescence) and Yn-BDP-ET (green ﬂuorescence) to visualize drug (EDLF analog) subcellular
localization. Mitochondria location was examined using MitoTracker (MIT, red ﬂuorescence). Areas of colocalization between edelfosine analogs and mitochondria in the
merge panels are purple (for PTRI-ET) or yellow (for Et-BDP-ET and Yn-BDP-ET). Images are representative of three independent experiments. Bar, 10mm
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Cell Death and DiseaseWe have previously shown that edelfosine induced DCm
disruption, followed by production of reactive oxygen species
(ROS) in leukemic cells.
18 To analyze whether ROS,
produced by the action of edelfosine on mitochondria, were
involved in edelfosine-induced mitochondrial swelling,
we tested the effect of free radical scavengers. As shown
in Figure 6c, Mn(III)tetrakis (4-benzoic acid) porphyrin
(MnTBAP), a non-peptidyl mimic of superoxide dismutase,
did not affect edelfosine-induced mitochondrial swelling,
suggesting that ROS do not contribute to edelfosine-induced
mitochondrial swelling.
Edelfosine-induced swelling in mitochondria is
mediated by lipid rafts. As edelfosine accumulates in
rafts
9–12,23 and we have found here that it also interacts
with mitochondria, we wondered whether cholesterol-rich
membrane domains could participate in the herein reported
edelfosine-promoted changes in isolated mitochondria. As
shown in (Figures 7a and b), disruption of membrane rafts
with the cholesterol-depleting agent MCD
14,17,19 inhibited
mitochondrial swelling induced by edelfosine (10mM) in
isolated mitochondria. A concentration-dependent effect of
MCD on edelfosine-induced mitochondrial swelling was
observed (Figure 7a). MCD pretreatment, at concentrations
of 2.5–5.0mg/ml, previously shown to deplete cholesterol,
19
signiﬁcantly inhibited edelfosine-induced mitochondrial
swelling (Figure 7a). Thus, the action of edelfosine on
isolated mitochondria was dependent on rafts present in
these organelles. MCD, when used at higher concentrations
(10mg/ml), compromised mitochondria, as it caused a direct
effect on mitochondrial swelling, even in the absence of
edelfosine (Figure 7a).
Colocalization of lipid rafts with mitochondria upon
edelfosine treatment. As both radioactive edelfosine and
its ﬂuorescent analog PTE-ET have been shown to accumulate
Figure 6 Edelfosine induces mitochondrial swelling. (a) Mitochondrial suspen-
sions were incubated in the absence (control) or in the presence of edelfosine
(EDLF, 5–50mM) or of the structurally related, but inactive, edelfosine analog ET-
18-OH (20–50mM). Edelfosine induces mitochondrial swelling in liver-isolated
mitochondria. Lines represent mean values of one experiment performed in
triplicate.(b) Histogramsrepresentmeans±S.D. of normalizedA540 at 2500s from
at least six different mitochondrial preparations. (c) Effect of CsA and free radical
scavenger MnTBAP on the mitochondrial swelling induced by edelfosine.
Mitochondrial suspensions were preincubated with CsA (10mM) or MnTBAP
(10nM) for 25min before edelfosine (10mM) addition (arrow in a). Data shown are
means±S.D. of normalized A540 at 2500s from at least three different
mitochondrial preparations. Signiﬁcant differences with respect to untreated
mitochondria were established at Po0.05 (*), Po0.01 (**) and Po0.001 (***)
levels by Student’s t-test
Figure 7 Disruption of rafts inhibits edelfosine-induced mitochondrial swelling.
(a) Mitochondrial suspensions were pretreated in the absence (control) or in the
presence of MCD (1–10mg/ml) for 35min, and then washed before incubation with
edelfosine (EDLF, 10mM) or vehicle. Histograms represent means±S.D. of
normalized A540 at 2500s from at least three different mitochondrial preparations.
Signiﬁcant differences with respect to control EDLF-treated mitochondria, in the
absence of MCD, were established at Po0.05 (*) and Po0.01 (**) levels by
Student’s t-test. (b) Mitochondrial suspensions were pretreated with MCD (2.5mg/
ml) for 35min and then washed before edelfosine incubation (EDLF, 10mM)
(arrow). Lines represent mean values of one experiment performed in triplicate
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5
Cell Death and Diseasein cholesterol-rich lipid rafts
9–12,23 and mitochondria are
cholesterol-poor organelles containing only 0.5–3% of the
sterol found in plasma membrane,
24 we hypothesized
whether edelfosine treatment led to a redistribution of lipid
rafts into the tumor cell. Rafts were visualized through
confocal microscopy, by using the raft marker ﬂuorescein
isothiocyanate (FITC)-cholera toxin (CTx) B subunit that
binds ganglioside GM1, mainly found in these domains,
14
whereas mitochondria were visualized by using MitoTracker
as above. As shown in Figure 8, rafts were mainly located at
the plasma membrane in untreated HeLa cells, whereas
mitochondria were observed as a widespread network in the
interior of the cell. After a 6-h incubation time, rafts largely
remained at the cell surface (Figure 8). Following edelfosine
treatment, rafts were gradually internalized into the cell,
whereas mitochondria clustered around the nuclei, leading to
a more intense ﬂuorescent signal. After 8-h incubation time, a
fraction of rafts were internalized, showing colocalization with
mitochondria (Figure 8). At later incubation times (17-h
incubation), a high proportion of rafts were already found in
the interior of the cell, colocalizing with clusters of
mitochondria that surrounded the nuclei (Figure 8). These
changes occurred almost simultaneously with the onset of
apoptosis in HeLa cells, which took place after 12–24h
incubation with edelfosine (Figure 1). Following 24-h drug
treatment, when cells underwent apoptosis, the charac-
teristic blebbing was observed with blebs enriched in rafts
(Figure 8). These data suggest that rafts are redistributed in
the tumor cell upon edelfosine treatment and eventually
interact with mitochondria. Our data unveil a link between
plasma membrane rafts and mitochondria driven by
edelfosine, and also suggest that cholesterol-rich lipid rafts
may have a role in mitochondrial-mediated processes in
cancer chemotherapy.
Figure 8 Colocalization of lipid rafts and mitochondria following edelfosine treatment. HeLa cells were untreated (control) or treated with 10mM edelfosine (EDLF) for the
indicated times. Rafts, identiﬁed by using FITC-CTx B subunit (rafts, green ﬂuorescence), and mitochondria, identiﬁed by using MitoTracker (MIT, red ﬂuorescence), were
visualizedbyconfocalmicroscopy.Areasof colocalizationbetweenraftsandmitochondriainthemergepanelsare yellow.Thecorrespondingdifferentialinterferencecontrast
(DIC) microscopy images are also shown. Nuclei were stained with DAPI (4’,6-diamidino-2-phenylindole) blue ﬂuorescent dye. Bar, 20mm
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Cell Death and DiseaseDiscussion
Lipid rafts and mitochondria show promise as targets in
cancer therapy because of their role in regulating apoptosis.
Here, through the synthesis of a number of ﬂuorescent
edelfosineanalogsthatpreservedtheproapoptoticfeaturesof
the parent drug, we have found for the ﬁrst time that an alkyl-
lysophospholipid analog colocalizes with mitochondria, and
thatedelfosineaffectsmitochondriainadirectway.Thiseffect
of edelfosine on mitochondria was dependent on lipid rafts. In
addition, treatment of cancer cells with edelfosine induced the
redistributionof rafts from plasma membrane to mitochondria,
involving a raft-mediated link between plasma membrane and
mitochondria. This interaction between edelfosine and mito-
chondria might explain the involvement of mitochondria in
edelfosine-mediated apoptosis,
3,17,18 and could provide an
insight on the role of lipid rafts in cancer chemotherapy and
mitochondrial-mediated apoptosis.
The interaction between edelfosine and mitochondria might
underlie the antitumor action of this ether phospholipid. We
have found here that disruption of rafts by cholesterol
depletion with MCD inhibited the mitochondrial swelling
induced by edelfosine. In this regard, it is worth to note that
edelfosine accumulates in rafts,
9–12,23 which might be
explained, at least in part, by the high afﬁnity of edelfosine
for cholesterol,
7,8 because of geometry compensation of the
‘cone shape’ of sterols and the ‘inverted cone shape’ of
edelfosine that leads to a stable bilayer.
8 Taken together,
these ﬁndings suggest the presence of cholesterol-containing
raft-like microdomains in mitochondria and their involvement
in edelfosine-induced effects on mitochondria.
The existence of raft-like domains in mitochondria is a
controversial issue, but increasing evidence supports their
presence.
25,26 Raft-like domains enriched in ganglioside GD3
and containing voltage-dependent anion channel protein 1
have been detected in mitochondria.
27 These mitochondrial
raft-like domains may represent preferential sites where
speciﬁc key processes leading to apoptosis take place, as
raft disruption in isolated mitochondria prevented edelfosine-
induced swelling (this work) and mitochondrial depolarization
induced by GD3 or tBid.
27 In this regard, the mitochondrial
pore-forming complex has been shown to contain chole-
sterol,
28 and an appropriate level of cholesterol in mitochon-
drial raft-like microdomains is crucial for the proper function of
mitochondria during apoptosis.
27 Cholesterol depletion by
MCD treatment has been recently shown to impair mitochon-
drial bioenergetics and to decrease calcium chloride-induced
swelling.
29 In rat liver mitochondria, cholesterol has been
shown to be mainly distributed within the outer membrane,
involvedinthecreationofmitochondriacontactsites,
30joining
mitochondrial membranes, where members of the PTP
complex, such as the voltage-dependent anion channel, are
localized in cholesterol-containing lipid raft-like areas.
31
The plasma membrane contains about 60–80% of total
cellular cholesterol, and it has been estimated that cholesterol
is as much as 30–40% of the lipid molecules in the plasma
membrane.
32 In contrast, mitochondria are considered
cholesterol-poor organelles, with estimates ranging from
0.5–3% of the content found in plasma membrane.
24
Interestingly, larger amounts of mitochondrial cholesterol
have been found in solid tumors. Mitochondrial cholesterol
levels in rat and human hepatoma cells were 3- to 10-fold
higher than in normal rat and human liver mitochondria.
33,34
Elevated mitochondrial cholesterol levels have been found to
be associated with tumor growth and malignancy, and
contribute to chemotherapy resistance.
34 Our previous
12
and present results indicate that this resistance seems to be
overcome by edelfosine, and the presence of rafts in
mitochondria would indeed facilitate the apoptotic action of
this ether phospholipid, likely, through its afﬁnity for choles-
terol.
7,8 Recently, we have shown in vitro and in vivo evidence
for the involvement of tumor cell cholesterol and rafts in the
antitumor action of edelfosine.
12,17,35 In addition, our present
ﬁndings suggest that edelfosine promotes colocalization of
rafts and mitochondria, suggesting that this ether phospho-
lipid induces internalization of rafts, or at least some of their
components, into mitochondria. In this regard, edelfosine has
been found to redistribute ergosterol from the plasma
membrane into the cell in Saccharomyces cerevisiae
yeasts.
13 Preliminary data suggest that cholesterol is inter-
nalized in HeLa cells following edelfosine treatment, with a
concomitant increase in the mitochondrial cholesterol level
(Mollinedo F and Gajate C, unpublished observations).
The results reported here suggest that edelfosine action
involves raft-like microdomains present in both plasma
membrane and mitochondria, and that cell surface rafts are
internalized to mitochondria following edelfosine treatment.
As edelfosine accumulates in rafts, this internalization of
cholesterol-containing raft-like microdomains into mitochon-
dria would favor the antitumor action of edelfosine and its
location in this organelle. After Fas/CD95 triggering, raft-like
microdomains have been detected on mitochondrial mem-
branes,
27 and edelfosine induces Fas/CD95 triggering in
cancer cells.
10,11,14,17,36 Both vesicular and non-vesicular
pathways move sterols between membranes and intracellular
compartments,
24,32 and a raft-modulated non-vesicular trans-
port of sterols from plasma membrane to endoplasmic
reticulum has been suggested.
37
GM1, which isabundant inrafts, hasbeen recentlyreported
to accumulate in the glycosphingolipid-enriched micro-
domains of mitochondria-associated endoplasmic reticulum
membranes, linking endoplasmic reticulum stress to Ca
2þ-
dependent mitochondrial apoptosis.
38 It is worthy to note that
edelfosine-induced apoptosis in HeLa cells has been shown
to be mediated by an endoplasmic reticulum stress response,
which releases endoplasmic reticulum-stored Ca
2þ and
requires mitochondria for the apoptotic outcome.
16 We have
previously found that edelfosine was mainly located in
endoplasmic reticulum in solid tumor cells.
15 Physical inter-
action between endoplasmic reticulum and mitochondria
39
could underlie this dual location of edelfosine in both
endoplasmic reticulum and mitochondria.
Our present results suggest a lipid raft interplay between
the cell surface and mitochondria, which might have a critical
role in the modulation of apoptosis, and therefore it may have
important clinical implications. How lipid rafts are involved in
this process remains to be elucidated. Here, we have found
that edelfosine affects directly mitochondria in a raft-depen-
dent way that would eventually lead to apoptosis. Our results
unveil new insights into the mechanism of action of
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mitochondria and apoptosis, thus opening new avenues for
cancer treatment.
Materials and Methods
Drugs and reagents. Edelfosine was from Apointech (Salamanca, Spain),
and stock solutions were prepared, as described previously.
3 Edelfosine analog
ET-18-OH,
3 was provided by M Modolell (Max-Planck-Institut fu ¨r Immunbiologie,
Freiburg, Germany). Cyclosporin (CsA) and MCD were from Sigma (St. Louis, MO,
USA). MnTBAP was purchased from Calbiochem (San Diego, CA, USA).
Cell culture and bcl-xL transfection. HeLa cells were grown in DMEM
culture medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum,
2mML-glutamine, 100units/ml penicillin and 100mg/ml streptomycin at 371Ci n5 %
CO2 humidiﬁed air. Cells were periodically tested for Mycoplasma infection and
found negative. HeLa cells were transfected with pSFFV-neo expression vector
containing the human bcl-xL open reading frame, driven by the long terminal repeat
of the splenic focus-forming virus (pSFFV-Bcl-xL), as previously described.
3,16 As a
control, transfection was performed with empty pSFFV-neo plasmid. Transfected
clones were selected by growth in the presence of 600mg/ml of G418 (Sigma) and
monitored by western blotting using the 2H12 anti-29kDa Bcl-xL monoclonal
antibody (BD Biosciences PharMingen, San Diego, CA, USA).
16 HeLa cells
transfectedwiththepSFFV-neoplasmidbehavedsimilarlytowild-typeHeLacells.
16
HeLacellsexpressed endogenousBcl-xL,butwesternblot analysisshoweda much
higher expression of Bcl-xL protein in bcl-xL-transfected HeLa cells.
16
Synthesis of ﬂuorescent edelfosine analogs. Detailed information
on the chemical synthesis and properties of the ﬂuorescent edelfosine analogs is
included in Supplementary Information.
Analysisofapoptosisbyﬂowcytometry. Quantitationofapoptoticcells
was determined by ﬂow cytometry as the percentage of cells in the sub-G1 region
(hypodiploidy) in cell cycle analysis, as previously described.
36
Cytoﬂuorimetric analysis of DWm. To evaluate the DCm, cells were
incubatedinPBSwith20nM3,30-DiOC6(3)(greenﬂuorescence;MolecularProbes,
Leiden, the Netherlands) for 20min at 371C, followed by analysis on a FACScan
cytoﬂuorimeter, as previously described.
18
Fluorescence microscopy. Cells were incubated with the distinct
ﬂuorescent edelfosine analogs for the indicated times, and with 100nM cell-
permeant MitoTracker probe (Molecular Probes) for 20min to label mitochondria,
and then processed and analyzed using a ﬂuorescence microscope (Axioplan 2;
Carl Zeiss MicroImaging Inc., Oberkochen, Germany) and a digital camera (ORCA-
ER-1394; Hamamatsu, Hamamatsu City, Japan), as previously described,
10 or
through confocal microscopy using a Zeiss LSM 510 laser scan confocal
microscope.
14 To visualize raft and mitochondria localization, untreated and
edelfosine-treated cells were labeled with the raft marker FITC-CTx B subunit, as
previously described,
14,17 and with MitoTracker as above. Then, cells were
analyzed with a Zeiss LSM 510 laser scan confocal microscope. Colocalization
assayswereanalyzedbyexcitationofthecorrespondingﬂuorochromesinthesame
section. Images were viewed and acquired by using a PLAN Apochromat  63/
1.40 NA oil-immersion objective lens and a Zeiss LSM 510 software version 3.5.
Mitochondria isolation for swelling assays. Mitochondria were
isolated from the livers of adult Sprague–Dawley rats by standard differential
centrifugation, aspreviouslydescribed.
40Brieﬂy,tissuewas manuallyhomogenized
with a Teﬂon pestle (Selecta, Barcelona, Spain) in solution I containing 230mM
mannitol, 70mM sucrose, 1mM EGTA, 2mM PMSF and 5mM HEPES, pH 7.4 on
ice. After centrifugation at 41C (106  g, 80s), the supernatant was layered onto
solutionII containing460mM mannitol,140mMsucrose,1mMEGTA,2mMPMSF
and 10mM HEPES, pH 7.4, and centrifuged (800 g, 3min). The top layer was
then centrifuged (2000 g, 5min), and the mitochondrial pellet resuspended in the
experimental buffer containing 215mM mannitol, 71mM sucrose, 10mM succinate
and 10mMHEPES,pH 7.4, and kepton ice until PTP determinations. Mitochondria
were used immediately after preparation. Mitochondrial protein content was
quantiﬁedbyusingaBCAproteinassayreagentkit(Pierce,Rockford,IL,USA),with
bovine serum albumin used as a standard.
Mitochondrial swelling. Mitochondria (0.7mg/ml) were incubated in
experimental buffer (215mM mannitol, 71mM sucrose, 10mM succinate and
10mMHEPES,pH7.4).Theswellingofmitochondriacausedbyaninﬂuxof solutes
across the inner membrane was measured by recording the decrease in
absorbance at 540nm in a spectrophotometer (Bio-Rad, Hercules, CA, USA).
Changes in absorbance at 540nm (A540), indicating mitochondrial swelling due to
PTP opening, were measured after addition of different compounds.
Cholesterol depletion. To deplete cholesterol, 2.5–3  10
5 cells/ml were
pretreated with 2.5mg/ml MCD (Sigma) for 35min at 371C in serum-free medium.
Cells were then washed three times and resuspended in complete culture medium
beforeedelfosineaddition,asdescribed.
19Todepletecholesterolinmitochondria,a
similar method was used with some slight modiﬁcations. Mitochondria were
incubated with 2.5mg/ml MCD for 35min at 41C in experimental buffer (215
mannitol, 71mM sucrose, 10mM succinate and 10mM HEPES, pH 7.4), and then
washed three times before edelfosine addition.
Statistical analyses. Results given are the mean (±S.D.) of the number of
experiments indicated. Statistical evaluation was performed by Student’s t-test.
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